Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease.
Loftus EV Jr, Griffith J, Neimark E, Song A, Wallace K, Nannapaneni S, Zhou J, Byrne R, Kligys K, Pang Y, Liao X, Kalabic J, Dubinsky M. Loftus EV Jr, et al. Among authors: kligys k. Adv Ther. 2023 May;40(5):2311-2325. doi: 10.1007/s12325-023-02477-2. Epub 2023 Mar 14. Adv Ther. 2023. PMID: 36917429 Free PMC article. Clinical Trial.
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
Ferrante M, Irving PM, Abreu MT, Axler J, Gao X, Cao Q, Fujii T, Rausch A, Torres J, Neimark E, Song A, Wallace K, Kligys K, Berg S, Liao X, Zhou Q, Kalabic J, Feagan B, Panaccione R. Ferrante M, et al. Among authors: kligys k. J Crohns Colitis. 2024 Mar 1;18(3):416-423. doi: 10.1093/ecco-jcc/jjad168. J Crohns Colitis. 2024. PMID: 37797293 Free PMC article. Clinical Trial.
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
Colombel JF, Schreiber S, D'Haens G, Rizzo J, Kligys K, Griffith J, Zambrano J, Zhou Q, Zhang Y, Kalabic J, Rieder F, Dubinsky MC, Panaccione R. Colombel JF, et al. Among authors: kligys k. J Crohns Colitis. 2024 Jun 3;18(6):818-827. doi: 10.1093/ecco-jcc/jjad206. J Crohns Colitis. 2024. PMID: 38069472 Free PMC article. Clinical Trial.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. Among authors: kligys k. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease.
Schreiber S, Cross RK, Panaccione R, D'Haens G, Bossuyt P, Dotan I, Colombel JF, Louis E, Dubinsky MC, Kligys K, Neimark E, Song A, Zambrano J, Kalabic J, Cheng E, Zhang Y, Ferrante M. Schreiber S, et al. Among authors: kligys k. Aliment Pharmacol Ther. 2024 Oct;60(7):897-906. doi: 10.1111/apt.18184. Epub 2024 Jul 25. Aliment Pharmacol Ther. 2024. PMID: 39054592 Clinical Trial.
Mucosal and Transmural Healing and Long-term Outcomes in Crohn's Disease.
Sands BE, Danese S, Chapman JC, Gurjar K, Grieve S, Thakur D, Griffith J, Joshi N, Kligys K, Dignass A. Sands BE, et al. Among authors: kligys k. Inflamm Bowel Dis. 2024 Jul 31:izae159. doi: 10.1093/ibd/izae159. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 39083264
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies.
Peyrin-Biroulet L, Colombel JF, Louis E, Ferrante M, Motoya S, Panaccione R, Torres J, Ungaro RC, Kligys K, Kalabic J, Zambrano J, Zhang Y, D'Haens G. Peyrin-Biroulet L, et al. Among authors: kligys k. Gastro Hep Adv. 2024 Mar 7;3(4):539-550. doi: 10.1016/j.gastha.2024.02.008. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39131711 Free PMC article.
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials.
Panaccione R, Ma C, Jairath V, Dignass A, Joshi N, Clark R, Griffith J, Kligys K, Semwal M, Smith Z, Mitchell D, Nunag D, Ferrante M. Panaccione R, et al. Among authors: kligys k. J Crohns Colitis. 2024 Aug 30:jjae128. doi: 10.1093/ecco-jcc/jjae128. Online ahead of print. J Crohns Colitis. 2024. PMID: 39212931
30 results